E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Refractory isolated systolic hypertension |
Hipertensión sistólica aislada refractaria |
|
E.1.1.1 | Medical condition in easily understood language |
Refractory isolated systolic hypertension |
Hipertensión sistólica aislada refractaria |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the effect on clinic pulse pressure of extended release isosorbide mononitrate vs placebo, added to the usual treatment of patients over 65 with refractory ISH, after 3 months of treatment. |
Comparar el efecto a 3 meses sobre la presión de pulso medida en la consulta, de mononitrato de isosorbide de liberación prolongada añadido al tratamiento habitual, en pacientes de 65 años o más con hipertensión sistólica aislada refractaria. |
|
E.2.2 | Secondary objectives of the trial |
1.- To quantify the effect on vascular function (estimated by central BP, augmentation index and pulse wave velocity) of extended release isosorbide mononitrate vs placebo, after 3 months of treatment.
2.- To compare the effect of the addition of extended releasese isosorbide mononitrate on previous parameters, depending on whether HT is truly refractory (mean 24 hour BP >130/80 mmHg) or pseudorefractory (?130/80 mmHg)
3.- To evaluate the safety profile of the strategy based on the addition of extended release isosorbide mononitrate, by the appearance of adverse effects (with particular attention to headache and orthostatic hypotension).
4.- To quantify the percentage of patients that reach a clinic sistolyc blood pressure <140mmHg in both treatments groups |
? Cuantificar el efecto sobre la presión arterial central y la elasticidad vascular, estimada por índice de aumento (IA) y velocidad de onda de pulso (VOP).
? Evaluar el perfil de seguridad terapéutico, mediante registro de efectos adversos (frecuencia, tipo, severidad y porcentaje de pacientes en los que son causa abandono).
? Cuantificar el porcentaje de pacientes que alcanzan presión arterial sistólica clínica (PAS) <140mmhg.
? Cuantificar el porcentaje de pacientes que alcanzan PAS media de 24 horas <130 mmHg en la MAPA.
? Cuantificar el efecto sobre la presión de pulso de 24 horas registrada en la MAPA. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
? Patients aged 65 or over of both genders, belong to some primary care or Hypertension?s Unit of Hospital La Princesa, who will be given their written informed consent to participate in the study.
? Patients with refractory ISH defined as SBP ?140 mmHg and DBP <90 mmHg, despite treatment with three drugs as maximum doses, one of them diuretic, during at least one month before the start
? Good adherence to treatment, defined as a good response to all questions of Morisky-Green?s test.
? SBP between 140 y 179 mmHg
? Ability to understand study procedures and to comply with them for the entire length of the study.
? Life expectancy greater than 1 year
? Signing the informed consent |
Se incluirán pacientes de ambos sexos, adscritos a los centros de salud participantes en el estudio o al Hospital Universitario de la Princesa, con los siguientes criterios:
? De 65 o más años, con HSA refractaria definida como PAS >=140 mmHg y PAD < 90 mmHg, a pesar de tratamiento con tres fármacos a dosis plenas, uno de ellos diurético, al menos durante el mes previo, en pacientes con buena adherencia la tratamiento.
? PAS entre 140 y 179 mmHg
? Esperanza de vida mayor a 1 año
? Firma del consentimiento informado |
|
E.4 | Principal exclusion criteria |
? Current treatment with nitrites or intolerance to them
? Atrial fibrillation
? Secondary hypertension
? Patients with physical, mental or important communications limitations.
? life expectancy less than one year
? Malignancy
? Congestive heart failure III-IV NYHA
? Renal failure IV-V (glomerular filtration measured with MDRD ?30 ml/min)
? Hepatic failure
? Concomitant treatment with phosphodiesterase 5 during previous month at the beginning of study
? Severe anaemia (haemoglobin ?8g/dl)
? Simultaneous participation in another clinical trial.
? Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
? Subjects who don?t give their written consent to participate in the study.
? Any other circumstance that, as the researcher criteria, advises against the inclusion to the study |
? PAS> 179 mmHg.
? Tratamiento con nitratos o intolerancia a los mismos.
? Contraindicación para el uso de nitratos ( hipersensibilidad, pacientes con glaucoma de ángulo cerrado).
? Tratamiento concomitante con inhibidores de la fosfodiesterasa 5 durante el mes previo al inicio del estudio.
? Fibrilación auricular.
? HTA secundaria.
? Pacientes con limitaciones físicas, psíquicas o de comunicación importantes
? Insuficiencia cardíaca congestiva estadíos III-IV de la NYHA.
? Insuficiencia renal estadios IV-V (filtrado glomerular estimado por MDRD ?30 ml/min).
? Insuficiencia hepática o enfermedad oncológica activa.
? Anemia severa (definida como hemoglobina ?8g/dl). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Difference between PP final visit and PP baseline visit: mmHg (office) |
El análisis primario de eficacia será la diferencia sobre la presión de pulso (PP) medida en la clínica, del tratamiento con mononitrato de isosorbide de liberación retardada frente a placebo . |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary efficacy assessment will be the difference between PP in the last visit compared to PP in the screening visit, and it will be demonstrated significantly differences compared to placebo. |
Diferencia entre la presión de pulso (PP) en la visita final respecto a la PP en la visita inicial, en mmHg., medida en consulta. |
|
E.5.2 | Secondary end point(s) |
- Difference between SBP( Systolic Blood Pressure)baseline visit and SBP final visit: mmHg (office)
- Difference between DBP(Diastolic Blood Pressure) baseline visit and DBP final visit: mmHg (office)
- Difference between PP(Pulse Pressure) baseline visit and PP final visit: mmHg (24 hours mean at ABPM,Ambulatory Blood Pressure Monitoring)
- Difference between SBP baseline visit and SBP final visit: mmHg (24 hours mean at ABPM)
- Difference between DBP baseline visit and DBP final visit: mmHg (24 hours mean at ABPM)
- Difference between PWV baseline(Pulse Wave Velocity) visit and PWV final visit
- Difference between Central SBP baseline visit and central SBP final visit
- Difference between Central PP baseline visit and central PP final visit
- Difference between AI baseline visit and AI final visit
- Percentage of subjects with SBP<140mmHg at office at the study end
- Percentage of responders subjects: decrease on SBP (baseline-final) >10 mmHg at office
- Percentage of subjects with adverse effects and type of adverse effect at 6 and 12 weeks after intervention
- Percentage of subjects that must abandon the study due to adverse effects.
- Percentage of patients with orthostatic hypotension (a decrease on SBP >20mmHg and/or DBP >10mmHg after one minute of standing) at each one of the visits |
? PP visita final- PP visita inicial: mmHg (consulta)
? PAS visita final- PAS visita inicial: mmHg (consulta)
? PAD visita final- PAd visita inicial: mmHg (consulta)
? PP visita final- PP visita inicial: mmHg (MAPA)
? PAS visita final- PAS visita inicial: mmHg (MAPA)
? PAD visita final- PAd visita inicial: mmHg (MAPA)
? VOP visita inicial- VOP visita final
? PAS central visita inicial- PAS central visita final
? IA visita inicial- IA central visita final
? % de sujetos con PAS < 140 al final del estudio
? % de sujetos respondedores: descenso de PAS > 10 mmHg
? % de sujetos con efectos adversos y tipo de efecto adverso.
? % de sujetos con hipotensión ortostática |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All of secondary objectives will be measured as the difference between the last visit compared to the inclusion visit. |
Todos los objetivos secundarios se medirán como la diferencia de las variables entre la última visita y la visita de inclusión del estudio. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 16 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Date on which the last subject completed the study follow-up visit. |
Fecha en la que el último sujeto completa la visita de seguimiento del estudio, ya que no están previstos análisis intermedios. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |